A new family of dinucleotide derivatives, diinosine polyphosphates, has been synthesized through the use of the enzyme 5Ј adenylic acid deaminase from Aspergillus sp., starting from the corresponding diadenosine polyphosphates. Functional studies were performed on rat brain synaptic terminals in which a dinucleotide receptor has been described that is specific for adenine dinucleotides. The results demonstrated that diinosine polyphosphates did not behave as agonists on the diadenosine polyphosphate receptor (also know as P 4 purinoceptor), but they were very efficient as antagonists in abolishing the Ca 2ϩ responses elicited by diadenosine pentaphosphate. The IC 50 values for diinosine triphosphate, diinosine tetraphosphate, and diinosine pentaphosphate were 4.90 Ϯ 0.10 M, 8.33 Ϯ 0.22 M, and 4.23 Ϯ 0.12 nM, respectively. The diinosine polyphosphates also antagonized the ATP receptors present in synaptic terminals, showing IC 50 values of 100.08 Ϯ 5.72 M for diinosine triphosphate, 29.51 Ϯ 1.40 M for diinosine tetraphosphate and 27.75 Ϯ 1.65 M for diinosine pentaphosphate. The antagonistic ability of these diinosine nucleotides was studied in comparison with other P 1 and P 2 purinoceptor antagonists, such as suramin, pyridoxalphosphate-6-azophenyl-2Ј,4Ј-disulfonic acid, and 8-cyclopentyl-1,3-dipropylxanthine. These purinergic antagonists did not inhibit the response of the P 4 purinoceptor; only the diinosine polyphosphates were able to act as antagonists on the dinucleotide receptor. Suramin and pyridoxalphosphate-6-azophenyl-2Ј,4Ј-disulfonic acid attenuated the responses elicited by ATP, as did the diinosine polyphosphate compounds. The most antagonistic diinosine polyphosphate for the dinucleotide and ATP receptors was diinosine pentaphosphate, which was 6000 times more selective for the P 4 purinoceptor than it was for the ATP receptor.
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Ap n As (where n ranges from three to six phosphates) are a family of compounds formed by two adenosine moieties bridged by a variable number of phosphates. These compounds are active substances in neural and non-neural tissues (1) . Their action is generally mediated by ATP purinergic receptors and in some cases by adenosine-like receptors in specific areas of the central nervous system (2, 3) . Recently, a new subtype of presynaptic receptor that is exclusive to Ap n As has been described in the central nervous system (4) . This receptor, characterized in rat brain synaptic terminals, has tentatively been termed P 4 purinoceptor, or dinucleotide receptor. The activation of the P 4 purinoceptor by Ap 5 A and Ap 4 A is coupled to the Ca 2ϩ entry to the synaptic terminals via a voltage-independent mechanism. The main feature of the dinucleotide receptor is the nonsensitivity to ATP and its synthetic analogs, being activated only by Ap n As (5) . Very recently, a receptor sensitive to Ap 4 A was also described in deermouse brain synaptosomes (6) .
Receptors for Ap n As and adenine nucleotides have been pharmacologically characterized by means of ATP synthetic analogs due to the scarcity and poor specificity of the available antagonists (7) . The use of agonistic profiles has not allowed a clear characterization of the receptors present in different tissues. Several compounds have been tested as P 2 antagonists, among which suramin and PPADS are still the most widely used (8, 9) . Although initially both were used to discriminate within different P 2 purinoceptor subtypes, only PPADS seems to be quite specific for the P 2X purinoceptors, with suramin suitable for distinguishing between P 1 and P 2 purinoceptors (10).
The existence of nonspecific adenylate deaminases isolated from organisms such as the snail Helix pomatia and microorganisms suc as Aspergillus sp. allows the enzymatic transformation of the Ap n As and adenosine nucleotides to inosine derivatives (11) . The transformation of Ap n A by adenylate deaminases yields compounds with the structure inosine(5Ј)oligophospho(5Ј)inosine (Ip n I). The Ip n Is could enlarge the number of different nucleotidic compounds acting as agonists or antagonists on purinergic receptors, especially on the P 4 purinoceptor, due to their structural similarities to Ap n As.
In the current study, we describe the synthesis of Ip n I from Aspergillus sp. by means of a commercial AMP deaminase. The relevant antagonistic properties of these dinucleotides on the P 4 purinoceptor and ATP receptors is reported in rat brain synaptic terminals. Special attention is devoted to Ip 5 I because its high antagonistic activity on Ap n A receptors makes this compound a useful tool with which to discriminate between ATP receptors and P 4 purinoceptors.
Experimental Procedures
Synthesis of Ip n Is. Ip n Is were obtained by starting with the corresponding Ap n As through the action of 5Јadenylic acid deaminase from Aspergillus sp. The enzyme (0.12 unit) was incubated with 10 mM Ap 3 A, Ap 4 A, or Ap 5 A in a final volume of 1 ml of 50 mM HEPES, pH 6.5. Incubation was carried out at 37°. Aliquots of 10 l were taken at different times, placed in a 100°water bath for 5 min (to stop the reaction), and diluted 1/100 with distilled water before injection into the HPLC system to follow the process of deamination. After 1.5 hr, the reaction was finally stopped by boiling the incubation mixture at 100°for 5 min followed by centrifugation at 13,000 ϫ g to eliminate the protein debris. Boiling did not affect the stability of the formed Ip n I as previously described for Ap n As (12) .
Treatment with phosphodiesterase from Crotalus durissus (EC 3.1.15.1) was carried out to verify the nature of the formed compounds. Aliquots of 15 l of the final reaction mixture were diluted 1:100 with distilled water and incubated with 3 munits of phosphodiesterase at 37°. Samples of 20 l were taken, at different times, to follow the appearance of the inosine mononucleotides by HPLC.
Chromatographic procedures. The chromatographic equipment consisted of a Waters (Milford, MA) 600E system controller, a Waters 717ϩ autosampler, and a 481 max spectrophotometer, all of which were managed by Millenium 2010 software running on an NEC 486DX computer. Analysis was performed under ion-pair chromatography conditions by equilibrating the chromatographic system with the following mobile phase: 0.1 mM KH 2 PO 4 , 2 mM tetrabutylammonium hydrogen sulfate, and 17% acetonitrile, pH 7.4. The column was a NovaPak C-18 (15-cm length, 0.4-cm diameter; Waters). Detection was monitored at 260-nm wavelength.
Synaptosomal preparation. Synaptosomes for functional studies were prepared from middle rat brain cerebral cortices of cervically dislocated and decapitated male Wistar rats (12) . Synaptosomal pellets containing 1 mg of protein were resuspended in 1 ml of incubation medium (122 mM NaCl, 3.1 mM KCl, 0.4 mM KH 2 PO 4 , 5 mM NaHCO 3 , 1.2 mM MgSO 4 , 10 mM glucose, and 20 mM TES, pH 7.4).
Intrasynaptosomal Ca 2؉ measurements. The cytosolic free calcium concentration was determined using Fura-2 as described by Grynkiewicz et al. (13) . Five minutes after resuspension, 1.33 mM CaCl 2 and 5 M Fura-2-acetoxymethyl ester were added. After incubation for 35 min, the synaptosomes were pelleted (through centrifugation at 800 rpm for 1 min), washed twice, and resuspended in fresh medium containing 1.33 mM CaCl 2 . Fluorescence was measured in a Perkin-Elmer Cetus (Norwalk, CT) Spectrofluorimeter LS-50 and monitored at 340 and 510 nm. Data were collected at 0.5-sec intervals.
Pharmacological studies. Ap 5 A and ATP were tested at a final concentration of 100 M. Also, Ip n Is were assayed at the same concentration before any antagonistic experiment was performed. The capacities of Ip 3 I, Ip 4 I, and Ip 5 I to act as possible antagonists was analyzed by assaying them at different concentrations ranging from 10 Ϫ10 to 10 Ϫ3 M. When tested as antagonists, Ip n Is were preincubated 2 min before the addition of the agonists. Other P 2 antagonists, such as suramin and PPADS, were assayed at a final concentration of 100 M 2 min before the application of the agonist. DPCPX, an A 1 adenosine antagonist, was preincubated at a final concentration of 250 nM at 2 min before the agonist was added to the synaptosomal preparation.
Studies were also performed to obtain the equilibrium dissociation constant (K B ) for Ip 5 I. A series of Ap 5 A dose curves (ranging from 10 Ϫ7 to 10 Ϫ3 M) were obtained in the presence of Ip 5 I at the following concentrations: 0, 4, 40, and 400 nM. These curves were analyzed according to the method of Stone and Angus (14) to obtain the K B value for the antagonist. 
Results
Chromatographic characterization of Ip n Is. Ip n Is were synthesized by starting with Ap n As through sequential deamination of both adenosine moieties. The 5Ј adenylic acid deaminase from Aspergillus sp. was very efficient with the three Ap n As that were converted to the corresponding Ip n I (Fig. 1) . The reaction had a yield of 100% after 1.5 hr with no further transformation of the products into other compounds. At the intermediate times, it was possible to note the presence of peaks with retention times between those of the initial Ap n A and the final Ip n I. It seems possible that those peaks could correspond to the intermediate reaction products in which one of the adenosines remain unchanged while the other had already been deaminated (Fig. 1) .
To verify the nature of the final products, samples of the putative Ip n Is were collected and incubated with phosphodiesterase from C. durissus. This enzyme cleaves dinucleotides giving a nucleotide monophosphate plus another mononucleotide with an nϪ1 phosphate. The presence of IMP and IDP was determined for the putative Ip 3 I ( Fig. 2A) , of IMP and ITP for Ip 4 I (Fig. 2B) , and of IMP and a compound putatively identified as inosine-5Ј-tetraphosphate for Ip 5 I (Fig. 2C) . In all of the Ip n I compounds treated with the phosphodiesterase, a gradual increase in the inosine mononucleotides and a disappearance of the dinucleotide were observed. Once the identity of the synthesized Ip n I was confirmed, they were assayed as active molecules in rat brain synaptic terminals.
Effect of Ip n Is on rat brain synaptic terminals. The application of Ip n Is to the rat brain synaptic terminals in a concentration of Յ100 M did not induce any Ca 2ϩ movement as a consequence of receptor activation (Fig. 3A) . Ap 5 A assayed at a concentration of 100 M elicited a Ca 2ϩ increase of 30.51 Ϯ 3.56 nM, as shown in Fig. 3A (basal synaptosomal Ca 2ϩ concentration before the agonist application, 115.08 Ϯ 5.12 nM).
Because the Ip n Is did not exert any agonistic effect on the rat brain synaptic terminals (Fig. 3A) , their capacity to act as a possible antagonists was tested. The incubation of the three Ip n Is at a final concentration of 100 M at 2 min before the Ap 5 A application reduced the Ca 2ϩ signal elicited by the Ap n A (Fig. 3B) . The treatment of synaptic terminals with other purinergic antagonists is shown in Fig. 3B . Suramin and PPADS, also at final concentrations of 100 M, did not mimic the effect of Ip n I. Suramin did not significantly modify the Ca 2ϩ entry induced through the P 4 purinoceptors, and PPADS surprisingly induced an enhancement of the signal compared with control (Fig. 3B) . Similar behavior to that exhibited by PPADS was shown by DPCPX (250 nM), which is known to antagonize adenosine receptors. Antagonistic effect of Ip n Is on the P 4 purinoceptor. Because Ip n Is behaved as antagonists on the dinucleotide receptor, they were preincubated in a wide range of concentrations in the presence of 100 M Ap 5 A. The Ca 2ϩ responses elicited by Ap 5 A were attenuated by all Ip n I to various degrees depending on the concentration and the diinosine compound assayed. An example of the antagonistic effect of one of these dinucleotides, Ip 5 I, is shown in Fig. 4A , in which a gradual attenuation of the Ca 2ϩ signal by higher doses of the Ip 5 I can be observed. Following a similar protocol inhibition, curves were obtained and analyzed to determined IC 50 val- ues for the three compounds ( (Fig. 4B) .
Various Ap 5 A series of dose-response curves were assayed in the presence of different concentrations of Ip 5 I to obtain the inhibition constant (K B ) of the antagonist for the receptor. The concentration-response analyses for Ap 5 A were performed in both the absence and the presence of the following concentrations: 4, 40, and 400 nM Ip 5 I (equivalent to IC 50 , 10-fold IC 50 , and 100-fold IC 50 value, respectively). As displayed in Fig. 5A , there was a gradual displacement of the dose-response curves to the right that was directly related to the increase in the antagonist concentration. EC 50 values were analyzed according to the Stone and Angus equation and represented as a Clark plot (Fig. 5, B and C) . The results obtained after the analysis yielded a K B value for Ip 5 I of 78.9 Ϯ 9.9 nM and a slope of 1.0 Ϯ 0.1, indicating the existence of a competitive antagonist mechanism.
Effects of Ip n Is on ATP responses. The antagonistic properties of the Ip n Is were also assayed for the ATP responses in isolated rat brain synaptic terminals. ATP (100 M) elicited a Ca 2ϩ increase of 25 Ϯ 2.7 nM (basal synaptosomal Ca 2ϩ concentration before the agonist application, 115.08 Ϯ 5.12 nM). (Fig. 6 and Table 1 ). Ip 5 I antagonized the Ca 2ϩ transients elicited by ATP, but the concentration required to attenuate the response compared with Ap 5 A was 6000 times higher, indicating that this Ip n I behaves as a good tool with which to discriminate between P 4 and P 2 receptors in rat brain synaptic terminals (Fig. 6A) .
Inosine mononucleotide effect on Ap 5 As and ATP Ca 2؉ transients. To find out whether inosine mononucleotides could mimic the effect of Ip n Is on both the dinucleotide and ATP receptor, ITP, IDP, and IMP were assayed as agonists/antagonists on the Ca 2ϩ transients elicited by 100 M Ap 5 A and ATP. ITP induced a Ca 2ϩ transient that did not abolish a secondary Ca 2ϩ response triggered by Ap 5 A. This result suggested that both nucleotides activate different receptors and that the antagonistic effect of the Ip n I compounds is indeed caused by them rather than by their degradation products (Fig. 7A) . None of the other inosine mononucleotides affected the responses elicited by Ap 5 A (Fig.  7B) . The application of ITP to the synaptosomal preparation before ATP produced a Ca 2ϩ increase that blocked the responses induced by ATP, suggesting that ITP and ATP share a purinergic receptor (Fig. 7A) . The other inosine mononucleotides, IDP and IMP, also exhibited direct effects on the Ca 2ϩ transients, and both attenuated the responses elicited by ATP (Fig. 7B) . 
Antagonists for the P 4 Purinoceptor

Discussion
The results that we present describe a simple method to synthesize Ip n I by starting with Ap n A. The synthesis procedure is similar to that described by Guranowski et al. (11) , but a commercial 5Ј adenylic acid deaminase from Aspergillus sp. is used instead one from the snail Helix pomatia. The effects of Ip 3 I, Ip 4 I, and Ip 5 I were tested on rat brain synaptic terminals, either alone or in the presence of Ap 5 A and ATP.
The lack of an action on the Ca 2ϩ transients by the three compounds suggested to us that they be studied as antagonists on the purinoceptors already characterized in rat brain synaptosomes (5) . The three Ip n Is completely blocked the effect of the best P 4 purinoceptor agonist (Ap 5 A). Ip 3 I and Ip 4 I presented a quite similar IC 50 value, in the micromolar range, that was higher than that exhibited by Ip 5 I, which was in the nanomolar range. This fact indicates some degree of structural requirement for the dinucleotide receptor, which is fulfilled by Ip 5 I (the closer structural antagonists compared with the best agonist, Ap 5 A) but not so well by the other antagonists. Extremely important is the IC 50 value for Ip 5 I, which was ϳ3 orders of magnitude lower than the micromolar values presented by the other diinosine compounds. Actions of Ap n A in the nanomolar range have been previously reported in neural models. For example, the neu- (17) .
Suramin and PPADS did not follow the antagonistic behavior displayed by the Ip n I on the P 4 purinoceptor. These results clearly contrast with those described in guinea pig urinary bladder, in which the effect of Ap 4 A is inhibited by suramin and especially by PPADS (18) . In this model and in the vas deferens, Ap n As seem to activate a P 2X purinoceptor (19, 20) , explaining why both suramin and PPADS antagonized the effect of Ap 4 A.
The effect of Ap 5 A was not blocked by the adenosine receptor antagonist DPCPX. This is an interesting point because in some central locations, such as the cerebral cortex and the hippocampus, the effect of Ap n A can be blocked by methylxanthines (2, 3). Nevertheless, a more detailed study on single CA3 hippocampal neurons revealed that extracellular Ap 5 A induced a Ca 2ϩ inward current that was not blocked by A 1 -and A 2 -specific antagonists. CA3 neurons possess dinucleotide receptors that have the same features as the purinoceptors characterized in this study (21) . The question of whether P 4 purinoceptors in CA3 neurons are also antagonized by Ip n Is is a topic to be investigated.
The Ip n Is did antagonize the responses elicited by ATP through other purinergic receptors different from the dinucleotide receptor. In this case, Ip 3 I, Ip 4 I, and Ip 5 I attenuated the Ca 2ϩ response induced by ATP with IC 50 values in the micromolar range. Although Ip 3 I and Ip 4 I were not very useful in discriminating between the P 4 and P 2 purinoceptors, this was not the case for Ip 5 I. Ip 5 I seems to be a good candidate for a dinucleotide receptor antagonist because it is 6000 times more effective on the P 4 purinoceptor than on the ATP receptor. This result could be at the origin of new pharmacological tools in the nucleotide receptor field. It is, nevertheless, necessary to take into consideration the features of the presynaptic model in which these experiments were performed.
Ap n A activity on metabotropic P 2 purinoceptors have been reported in many tissues (4, 22) . The human P 2U purinoceptor is extremely sensitive to Ap 4 A, and this dinucleotide has been suggested to be a physiological regulator of this receptor (23) . Also, receptors for Ap n As described in heart (24 -26) and mouse brain (6, 21) would be good models in which Ip n I compounds could be assayed to establish pharmacological criteria for the classification of the dinucleotide receptors.
It is well known that Ap n As are inactivated by the action of high affinity ectodinucleotide hydrolases (27, 28) . Based on the results of the current study, possible Ip n I formation at the extracellular level by an unidentified adenylate deaminase cannot be ruled out. Further studies are necessary to demonstrate this possibility and its physiological relevance.
In summary, deamination products of Ap n As should be considered when studying the nucleotide receptors. The selectivity of Ip 5 I in antagonizing the dinucleotide receptor suggests that this substance could be an appropriate compound with which to identify P 4 purinoceptors in biological systems.
